Jia Zhu

Dr. Jia Zhu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BZBoxuan Zhou
Boxuan Zhou
ZMZhaohong Mo
Zhaohong Mo
GLGuie Lai
Guie Lai
XCXiaohong Chen
Xiaohong Chen
RLRuixi Li
Ruixi Li
FZFang Zheng
Fang Zheng
Background: Circular RNAs (circRNAs) have important regulatory functions in cancer, but the role of circRNAs in the tumor microenvironment (TME) remains unclear. Moreover, we also explore the effects of si-circRNAs loaded in nanoparticles as therapeutic agent for anti-tumor in vivo. Methods: We conducted bioinformatics analysis, qRT-PCR, EdU assays, Transwell assays, co-culture system and multiple orthotopic xenograft models to investigate the expression and function of circRNAs. Additionally, PLGA-based nanoparticles loaded with si-circRNAs were used to evaluate the potential of nanotherapeutic strategy in anti-tumor response. Results: We identified oncogene SERPINE2 derived circRNA, named as cSERPINE2, which was notably elevated in breast cancer and was closely related to poor clinical outcome. Functionally, tumor exosomal cSERPINE2 was shuttled to tumor associated macrophages (TAMs) and enhanced the secretion of Interleukin-6 (IL-6), leading to increased proliferation and invasion of breast cancer cells. Furthermore, IL-6 in turn increased the EIF4A3 and CCL2 levels within tumor cells in a positive feedback mechanism, further enhancing tumor cSERPINE2 biogenesis and promoting the recruitment of TAMs. More importantly, we developed a PLGA-based nanoparticle loaded with si-cSERPINE2, which effectively attenuated breast cancer progression in vivo. Conclusions: Our study illustrates a novel mechanism that tumor exosomal cSERPINE2 mediates a positive feedback loop between tumor cells and TAMs to promote cancer progression, which may serve as a promising nanotherapeutic strategy for the treatment of breast cancer.

15 July 2025 in Biochemical Pharmacology
Verified
Journal Article
Open access
LYLiping Yan
Liping Yan
QTQi-xing Tan
Qi-xing Tan
JZJia Zhu
Jia Zhu
YHYongfei He
Yongfei He
TPTao Peng
Tao Peng
JHJianxin He
Jianxin He
Breast cancer liver metastasis presents a significant clinical challenge, requiring a deeper understanding of its underlying mechanisms. In this study, we explored the role of serum metabolites and gut microbiota in breast cancer liver metastasis, with a particular focus on the effects of glycochenodeoxycholic acid sodium salt (GCDC). Serum metabolites were analyzed using liquid chromatography-mass spectrometry (LC-MS), while gut microbiota composition was assessed through 16S rDNA sequencing of stool samples. Statistical analyses revealed a strong correlation between gut microbiota and GCDC levels, which varied markedly among breast cancer, breast cancer liver metastasis, and healthy control groups. GCDC was identified as a microbiota-related metabolite through high-throughput bioinformatics screening. In vitro experiments showed that GCDC inhibited breast cancer cell proliferation, migration, and invasion while inducing cell death. In vivo, GCDC treatment reduced subcutaneous tumor growth and prevented liver metastases, as evidenced by decreased Ki67 expression in tumor tissues. These findings suggested that GCDC suppresses breast cancer liver metastasis by inhibiting cancer cell growth and migration, underscoring its potential as a biomarker for early detection and a therapeutic agent for liver metastasis in patients with breast cancer. Further research is needed to clarify its mechanisms and explore its clinical applications.

4 December 2025 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Open access
YTYuanyan Tang
Yuanyan Tang
XHXing Huang
Xing Huang
ZLZhongzeng Liang
Zhongzeng Liang
XYXiaoting Yu
Xiaoting Yu
ZLZhengren Liu
Zhengren Liu
JZJia Zhu
Jia Zhu
Current single preoperative lymphatic imaging technique are inadequate to ensure the simplification and enhanced efficiency of lymphatic venous anastomosis (LVA) procedures. The application value of contrast-enhanced ultrasound (CEUS) examination combined with ultra-high-frequency ultrasound (UHFUS) examination in LVA has not been explored. This study aimed to systematically explore the clinical application value of CEUS examination integrated with UHFUS examination in guiding LVA. Patients undergoing LVA after localization with indocyanine green (ICG) lymphography (group B) or CEUS examination combined with UHFUS examination (group A) from November 1, 2023, to March 1, 2025, were enrolled sequentially. Preoperative localization time and number of lymphatic vessels (LVs), skin incision length, time and number of LVs anastomoses during LVA, postoperative reduction in the maximum circumference of the affected limb, and improvement in subjective symptoms were compared. A total of 19 patients with lymphedema who underwent LVA were included in our study. Compared with indocyanine green, CEUS combined with UHFUS examination can shorten preoperative LVs localization time, increase the number of end-to-end anastomoses during LVA, streamline the LVA procedure, and improve patient symptoms to some extent. CEUS combined with UHFUS examination is a promising method for the preoperative evaluation of LVs that can enhance the efficiency and feasibility of LVA.